Furthermore, in designing a HIF-1α-targeting clinical trial, it would be important to optimize the assessment of HIF-1α expression by using a panel of antibodies to accurately identify subgroups of ovarian carcinoma patients who could benefit from novel HIF-1α-inhibiting therapeutic strategies. Here, HIF1A is linked to ovarian carcinoma.